The week in health tech, explained in plain English.Get the free newsletter →
November 12, 2026

Takeaways from the most recent news in the technology and policies shaping healthcare.

Finance

Four Hospitals Under Financial Strain as Medicaid Cuts Loom

Hospital closures in 2026 are pacing behind 2025, but financial distress is still widespread across the sector, according to Becker's Hospital Review. The publication flagged four hospitals it reported on in the past month that are under strain, including Watsonville Community Hospital in California.

The pressures are familiar and compounding. Low patient volumes squeeze revenue, cash reserves are shrinking, and reimbursement losses eat into already thin margins. Layered on top is the prospect of federal Medicaid cuts under HR 1, which threatens a major funding source for hospitals that serve large shares of low-income patients. Facilities already operating close to the edge have little cushion to absorb another hit.

For operators and investors, the takeaway is that a slower closure pace does not signal recovery. Many hospitals remain fragile, and the coming Medicaid changes could tip borderline facilities toward service cuts, consolidation, or shutdown, especially in rural and safety-net markets where alternatives are scarce.

More in Finance

Finance

McLeod Health Operating Income Drops 9.7% as Costs Rise

McLeod Health's operating income fell 9.7% to $137.5 million in fiscal 2026 as expenses grew faster than its 8% revenue increase.

Why it matters: It shows that even revenue-growing health systems are losing margin as costs outpace reimbursement.

Finance

Novartis Lp(a) Drug Lowers Risk Marker but Fails on Outcomes

Novartis's pelacarsen lowered the cardiovascular risk marker Lp(a) but failed to reduce heart attacks or strokes, undermining a major industry strategy.

Why it matters: A failed outcomes trial for a leading Lp(a) drug threatens billions in cardiovascular research built on the assumption that lowering the marker prevents events.

Finance

Novo's Ziltivekimab Flops, But Cardiologists Stay Bullish

Novo Nordisk's ziltivekimab missed in the ZEUS cardiovascular trial, but cardiologists say the anti-inflammatory approach to heart disease remains valid.

Why it matters: Anti-inflammatory therapy is one of the biggest bets in cardiovascular medicine, and how the field reacts to a high-profile failure shapes billions in future R&D.